HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. develops and markets technology for complex molecular profiling and biomarker development.
Founded
1997HTG Molecular Diagnostics, Inc. develops and markets technology for complex molecular profiling and biomarker development.
HTG Molecular Diagnostics, Inc., founded in Tucson, United States, is dedicated to advancing the field of molecular profiling and biomarker development. The company's core mission is to facilitate the routine use of complex molecular profiling through its innovative technology platform. HTG offers a comprehensive suite of products including instrumentation, consumables, and software analytics designed for applications such as tumor profiling, molecular diagnostic testing, and biomarker development. Their market focus spans across research institutions, clinical laboratories, and pharmaceutical companies.
Notable affiliated individuals and investors include key figures in the biotechnology and healthcare sectors, although specific names are not provided. HTG Molecular Diagnostics has achieved significant milestones in the development and commercialization of their HTG EdgeSeq technology, which has been widely adopted for its efficiency and accuracy in gene expression profiling. The company's impact is evident in its contributions to personalized medicine and precision diagnostics, enhancing the ability to understand and treat complex diseases at a molecular level.
Companies similar to HTG Molecular Diagnostics include Myriad Genetics, Molecular Biometrics, Molecular Detection and Molecular Health.
HTG Molecular Diagnostics was founded in 1997.
HTG Molecular Diagnostics' headquarters is located in Tucson, AZ, US.
HTG Molecular Diagnostics' most recent funding round was for $10M (USD) in December 2022.
As of Dec 21, 2022, HTG Molecular Diagnostics has raised a total of $106.5M (USD).
HTG Molecular Diagnostics has 107 employees as of Feb 5, 2024.
Molecular Detection
